Post-Transplantation Diabetes Mellitus

Syed Haris Ahmed, Kathryn Biddle, Titus Augustine, Shazli Azmi

Research output: Contribution to journalReview articlepeer-review


Solid organ transplantation (SOT) is an established therapeutic option for chronic disease resulting from end-stage organ dysfunction. Long-term use of immunosuppression is associated with post-transplantation diabetes mellitus (PTDM), placing patients at increased risk of infections, cardiovascular disease and mortality. The incidence rates for PTDM have varied from 10 to 40% between different studies. Diagnostic criteria have evolved over the years, as a greater understating of PTDM has been reached. There are differences in pathophysiology and clinical course of type 2 diabetes and PTDM. Hence, managing this condition can be a challenge for a diabetes physician, as there are several factors to consider when tailoring therapy for post-transplant patients to achieve better glycaemic as well as long-term transplant outcomes. This article is a detailed review of PTDM, examining the pathogenesis, diagnostic criteria and management in light of the current evidence. The therapeutic options are discussed in the context of their safety and potential drug-drug interactions with immunosuppressive agents.

Original languageEnglish
JournalDiabetes Therapy
Publication statusPublished - 24 Feb 2020


Dive into the research topics of 'Post-Transplantation Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this